Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Learn smart investing strategies for stocks, ETFs, bonds, and building long-term wealth.
17,689 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Jim Cramer remains wary of Salesforce as growth slows and CIOs shift budgets to less expensive software. He argues th...
Boise remains a retirement magnet, but costs have risen. With a $900K pot, a paid-off home, and careful tax and cash-...
As valuations run high, retirement plans face tighter assumptions. Experts urge conservative return targets and diver...
Tech earnings are delivering impressive results, yet portfolio risk is rising as technology carries a larger share of...
Looking to boost income and growth in the second half of 2026? These three dividend ETFs blend quality, yield, and re...
Meta's cloud moves are changing the AI compute landscape. This article breaks down what meta's cloud news just means ...
A new set of futures is coming to the CME Group, tying Tesla and SpaceX to a cash-settled futures contract. This arti...
Broadcom stock rallied Thursday morning, delivering a notable move for a semiconductor leader. This article breaks do...
Micron looks cheaper than its earnings prospects suggest, but a closer look reveals cyclicality, demand swings, and r...
When a company’s CFO sells shares, investors want to know if it’s a red flag or routine planning. This analysis uses ...
Tech giants swing on headlines. This guide unpacks why meta stock dropped then, how the rebound happened, and what in...